NCT02456857View on ClinicalTrials.gov

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 12, 2016

Primary Completion Date

May 24, 2023

Study Completion Date

May 24, 2023

Conditions

Invasive Breast CarcinomaTriple-Negative Breast Carcinoma

Interventions

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Everolimus

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pegylated Liposomal Doxorubicin Hydrochloride

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER

NCT02456857 - Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | Biotech Hunter | Biotech Hunter